Abstract Library

#3787 PRESTO 3 – An international, simulated-use study to assess nurses’ preferences between two lanreotide injection syringes (Somatuline Autogel vs Pharmathen) for patients with neuroendocrine tumors (NETs) and/or acromegaly

Introduction: Somatostatin analogues (SSAs) are often used to treat patients with NETs and acromegaly. The Pharmathen syringe is now available in Europe and the USA for depot injection. It is important for decision making when using SSAs that there is confidence in and ease of use with any syringe.

Conference:

Presenting Author: Ferone D

Authors: Grossman A, Martin W, Williams J, Houchard A, Pommie C,

Keywords: Gastroenteropancreatic neuroendocrine tumor, Simulated use study, Somatostatin analogues, User preference,

#3334 Utility of midpoint imaging in patients receiving peptide receptor radionuclide therapy (PRRT) for advanced progressive midgut neuroendocrine tumors (NET)

Introduction: The NETTER-1 trial formed the basis for standard practice of PRRT, consisting of 4 cycles with follow-up imaging during midtreatment and after completion to evaluate disease response. However, in clinical practice the timing of midpoint imaging varies if performed at all, and it is unclear how often it influences subsequent management.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Norman A, Wee C, Hobday T, Kendi A, Johnson G,

Keywords: midpoint imaging, PRRT, clinical decision making,

#3164 Automatized hepatic tumor volume analysis of neuroendocrine liver metastases by Gd-EOB MRI - A deep learning model to support multidisciplinary cancer conference decision making

Introduction: Rapid quantification of liver metastasis for diagnosis and follow-up is an unmet medical need in patients with secondary liver malignancies.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Fehrenbach U

Authors: Fehrenbach U, Xin S, Hartenstein A, Auer T, Dräger F,

Keywords: liver metastases, automatised 3D quantification, deep learning, hepatic tumor load, response evaluation, MRI,

#3106 Advanced small intestine well-differentiated neuroendocrine tumors (WD-SiNET): A survey of practice on 3rd line treatment

Introduction: Selection of third-line treatment after somatostatin analogues (SSA) and Peptide Receptor Radionuclide Therapy (PRRT) for WD-SiNETs remains challenging.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lamarca A

Authors: Lamarca A, Cives M, de Mestier L, Crona J, Spada F,

Keywords: small bowel, well-differentiated, third-line, everolimus, IFN, chemotherapy, liver embolisation, multidisciplinary, survey, decision making,

#3045 Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with MEN1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort

Introduction: Pancreatic neuroendocrine tumors (pNETs) are the most lethal manifestation in patients with multiple endocrine neoplasia type 1 (MEN1). Tumor size is still regarded as the main prognostic factor and therefore used for surgical decision making.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: van Beek D

Authors: van Beek D, Verkooijen H, Bonsing B, van Eijck C, van Goor H,

Keywords: Multiple endocrine neoplasia type 1, pancreatic neuroendocrine tumor, reliability, agreement, computed tomography, magnetic resonance imaging, endoscopic ultrasonography, pathology,